Homozygous Familial Hypercholesterolemia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pharma, Sa

DelveInsight's "Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In March 2022, Evkeeza® (evinacumab-dgnb), which has been approved by the Food and Drug Administration (FDA), is used to treat children with homozygous familial hypercholesterolemia (HoFH) who are 5 to 11 years old. A completely human monoclonal antibody called evinacumab binds to and inhibits the activity of angiopoietin-like 3 (ANGPTL3). The approval was based on data from a 3-part single-arm, open-label experiment (ClinicalTrials.gov Identifier: NCT04233918), Part B of which included 14 paediatric patients with HoFH, with an average age of 9 years. The trial's efficacy and safety were assessed
• In the 7MM, there were roughly 2,845 diagnosed prevalent cases of Homozygous Familial Hypercholesterolemia. By 2032, these cases are anticipated to rise at a CAGR of 0.3% over the research period (2019-2032)
• There were predicted to be 1,349 diagnosed prevalent cases of Homozygous Familial Hypercholesterolemia in the US. Throughout the study period (2019-2032), it is anticipated that these cases will rise.
• The EU4 and the UK made up about 38% of all diagnosed prevalent Homozygous Familial Hypercholesterolemia cases among the 7MM, and it is anticipated that this number would rise over the study period
• Around 1,214 Homozygous Familial Hypercholesterolemia cases resulting from LDLR gene mutations were reported in 2022, followed by 67 cases of APOB, 54 cases of other mutations (LDLRAP1, APOE, SREBP2, STAP1), and 13 cases of PCSK9 gene mutation in the US.
• Key Homozygous Familial Hypercholesterolemia Companies: Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, LIB Therapeutics LLC, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, lerodalcibep, Lomitapide, and others
• The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

Homozygous Familial Hypercholesterolemia Overview
A uncommon and serious hereditary condition called HoFH alters how cholesterol is metabolised. It is a hereditary disorder brought on by mutations in either one or both copies of the LDLR (low-density lipoprotein receptor) gene or other genes involved in the metabolism of cholesterol, such as APOB or PCSK9.

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Report
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:
The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Homozygous Familial Hypercholesterolemia
• Prevalent Cases of Homozygous Familial Hypercholesterolemia by severity
• Gender-specific Prevalence of Homozygous Familial Hypercholesterolemia
• Diagnosed Cases of Episodic and Chronic Homozygous Familial Hypercholesterolemia
Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Homozygous Familial Hypercholesterolemia Therapies and Key Companies
• ARO-ANG3: Arrowhead Pharmaceutical
• LEQVIO (inclisiran/KJX839): Novartis/ Alnylam Pharmaceutical
• Lerodalcibep (LIB003): LIB Therapeutics
• Lomitapide: Amryt Pharma
• Inclisiran: Novartis
• Evinacumab: Ultragenyx Pharma
• ARO-ANG 3 Injection: Arrowhead Pharma
• Alirocumab: Sanofi
• CER-001: Cerenis Therapeutics, SA
• ALN-PCSSC: The Medicines Company
• lomitapide: Aegerion Pharmaceuticals, Inc.
• AK102: Akeso
• AEGR-733: Aegerion Pharmaceuticals, Inc.
• lerodalcibep: LIB Therapeutics LLC
• Lomitapide: Aegerion Pharmaceuticals, Inc.

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Market
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Homozygous Familial Hypercholesterolemia Market Strengths
• The clarity in disease understanding and pathogenesis have driven the development of novel pharmacological options like PCSK9 inhibitors, ANGPTL3 inhibitor, and MTP inhibitor.
• Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly

Homozygous Familial Hypercholesterolemia Market Opportunities
• Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
• Advancements in healthcare technologies and digital health solutions can potentially enhance the early detection and personalized management of HoFH

Scope of the Homozygous Familial Hypercholesterolemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Homozygous Familial Hypercholesterolemia Companies: Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Amryt Pharma, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, LIB Therapeutics LLC, Regeneron Pharmaceuticals Inc, RegenxBio Inc, The Medicines Company, and others
• Key Homozygous Familial Hypercholesterolemia Therapies: ARO-ANG3, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, lerodalcibep, Lomitapide, and others
• Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
• Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Homozygous Familial Hypercholesterolemia Unmet Needs, KOL's views, Analyst's views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Therapeutic Assessment https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Homozygous Familial Hypercholesterolemia Market Report Introduction
2. Executive Summary for Homozygous Familial Hypercholesterolemia
3. SWOT analysis of Homozygous Familial Hypercholesterolemia
4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance
5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance
6. Homozygous Familial Hypercholesterolemia Disease Background and Overview
7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia
9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices
10. Homozygous Familial Hypercholesterolemia Unmet Needs
11. Homozygous Familial Hypercholesterolemia Emerging Therapies
12. Homozygous Familial Hypercholesterolemia Market Outlook
13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2019-2032)
14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies
15. Homozygous Familial Hypercholesterolemia Market Drivers
16. Homozygous Familial Hypercholesterolemia Market Barriers
17. Homozygous Familial Hypercholesterolemia Appendix
18. Homozygous Familial Hypercholesterolemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Homozygous Familial Hypercholesterolemia Pipeline https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Homozygous Familial Hypercholesterolemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Homozygous Familial Hypercholesterolemia market. A detailed picture of the Homozygous Familial Hypercholesterolemia pipeline landscape is provided, which includes the disease overview and Homozygous Familial Hypercholesterolemia treatment guidelines.
Homozygous Familial Hypercholesterolemia Epidemiology https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Homozygous Familial Hypercholesterolemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Homozygous Familial Hypercholesterolemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.